Login to Read
An artist's rendition of the completed expansion.
Merck Animal Health (formerly Intervet/Schering-Plough Animal Health) is expanding its Netherlands vaccine manufacturing unit at its Biosciences Center Boxmeer campus, which will result in a doubling of the capacity of its Tissue Culture Department, one of the departments where antigens for viral and parasitological vaccines are manufactured for international markets.
The $18 million investment, which is scheduled to be complete by early 2013, has been designed to operate with optimal efficiency and takes into account the anticipated globally growing demand for veterinary vaccines. In addition, the increase of the manufacturing capacity that will be realized anticipates for large-scale emergency production of veterinary vaccines when extensive amounts are needed within a short time period such as during outbreaks of emerging diseases.
The Tissue Culture Department Boxmeer is an EU-GMP licensed facility and produces viral and parasitological antigens that are used as active components of veterinary vaccines. The department specializes in complex biotechnological production processes that require high flexibility, using roller bottles, cell factories and other suitable cell and virus culture and purification systems. In 2010, the department produced 12 different antigens, totaling almost 300 million vaccine doses for cattle, horses, dogs, cats, fish and swine.
Lon Bohannon to be succeeded by industry veteran Stephen Snyder
Animal agribusiness needs to tell its side of the story on antimicrobial use in modern production
Pork industry optimistic trade partnerships will remove many barriers
Video part of project to increase transparency in meat, poultry industry
Transatlantic research group is studying the fast mutating virus that costs pork producers millions of pounds each year.
Members to help guide company's FarmCheck program
--- Thank you for your patience ----
If you have any issues logging in or any other need feel free to contact us.